FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, D.C. 20549

STATEMENT (OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Goldberg Mark Alan					2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]						(Che	5. Relationship of Reportin (Check all applicable) X Director		ng Person(s) to Issuer 10% Owner			
(Last) 41 GRA	(F SMERE RC	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/12/2013							Officer (below)	(give title	Other (specify below)		pecify	
(Street) NEEDH. (City)		IA tate)	02494 (Zip)					of Original F			,	Line	Form fil Form fil Person	ed by One ed by More	Repor	(Check App ting Person One Report	
1. Title of Security (Instr. 3) 2. Transa Date			2. Transact	2A. Deemed Execution Date,		te, Transaction Code (Instr.		(A) or	5. Amoun	illy	Form:	Direct I Indirect E tr. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)				
							Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 and				(111501.44)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	vative Conversion Date urity or Exercise (Month/Day/Year) if any		Code	ransaction of Derivati Securiti Acquire (A) or Dispose of (D) (II		erivative ecurities cquired A) or		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Deferred Share Unit	\$0 ⁽¹⁾	11/12/2013		A		3,000		02/01/2014 ⁽³	3)(2)	(2)	Common Stock ⁽²⁾	3,000	\$0 ⁽¹⁾	3,000		D	
Stock option (right to buy)	\$14.7	11/12/2013		A		10,000		02/01/2014	(4)	11/12/2023	Common Stock	10,000	\$14.7	10,000)	D	

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- 3. The deferred share units vest ratably over a one year period in quarterly increments beginning on February 1, 2014, contingent upon the individual remaining a director as of each vesting date.
- 4. Exercisable as to 2,500 shares commencing on February 1, 2014, 2,500 shares commencing on May 1, 2014, 2,500 shares commencing on August 1, 2014 and 2,500 shares commencing on November 1, 2014, contingent upon the individual remaining a director as of each vesting date.

/s/ Craig Barrowns, attorney in

11/13/2014

<u>fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.